여성 성기능 장애 치료 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of female sexual dysfunction (FSD) treatment Market

The global female sexual dysfunction (FSD) treatment market was valued at USD 537.19 million in 2025 and is projected to grow from USD 595.74 million in 2026 to USD 1,655.08 million by 2034, registering a strong CAGR of 13.62% during the forecast period. North America dominated the market with an 88.90% share in 2025, driven by high awareness, strong prescription rates, and robust R&D investments. The U.S. market is projected to reach USD 782.3 million by 2032, reflecting continued innovation and treatment adoption.

Female sexual dysfunction refers to persistent or recurrent issues related to sexual desire, arousal, response, or pain that cause distress. Conditions such as dyspareunia, hypoactive sexual desire disorder (HSDD), and genito-pelvic penetration pain disorder (GPPPD) are particularly prevalent among post-menopausal women due to declining estrogen levels. Additionally, chronic illnesses such as diabetes, cancer, and cardiovascular diseases increase the likelihood of sexual dysfunction, thereby driving treatment demand.

Market Trends

A key trend in the market is the growing focus on hormonal therapies, particularly estrogen-based treatments. Local estrogen therapies (LET), including creams, vaginal tablets, capsules, and rings, are widely prescribed for menopausal symptoms such as dyspareunia and vaginal dryness. In 2026, the estrogen therapy segment accounted for 59.36% of the market share, owing to its effectiveness, affordability, and ease of administration.

Pharmaceutical companies are expanding their estrogen product portfolios and securing regulatory approvals in new regions. Increased sales of products such as Imvexxy and Osphena highlight the rising adoption of vaginal estrogen therapies. Additionally, ongoing clinical trials for innovative therapies, including topical sildenafil cream and other non-hormonal treatments, are expanding the treatment landscape.

COVID-19 Impact

The COVID-19 pandemic temporarily hindered market growth in 2020 due to lockdowns, restricted hospital visits, and reduced drug availability. Prescription volumes declined, and sales of key products such as Intrarosa dropped significantly during the pandemic. However, post-pandemic recovery, telehealth expansion, and improved access to online pharmacies restored treatment demand. Strategic initiatives such as digital health partnerships and expanded product commercialization helped stabilize the market.

Market Growth Drivers

Rising R&D Investments

The potential side effects associated with hormonal therapies have increased demand for safer, non-hormonal alternatives. As a result, pharmaceutical companies are investing heavily in research and development to introduce innovative drugs with improved safety profiles. Manufacturing expansions and licensing agreements are further strengthening product availability across global markets.

Increasing Disease Prevalence

The prevalence of dyspareunia and HSDD among women, especially post-menopausal populations, is rising globally. Studies indicate high rates of sexual dysfunction among women with chronic conditions. Growing awareness of women's sexual health and increased medical consultations are contributing to higher diagnosis and treatment rates, supporting the market's projected expansion to USD 1,655.08 million by 2034.

Restraining Factors

Despite growth prospects, low awareness remains a significant barrier. A large proportion of women are unaware of sexual dysfunction disorders or available treatments. Social stigma and reluctance to seek medical consultation further limit adoption. Additionally, limited awareness of hormonal and non-hormonal therapies in developing regions restricts market penetration.

Market Segmentation Analysis

By Drug

The market is segmented into flibanserin, bremelanotide, ospemifene, estrogen therapy, and others. The estrogen therapy segment dominated with 59.36% share in 2026, driven by high prescription rates for menopausal symptoms. Meanwhile, non-hormonal therapies are expected to witness strong growth during the forecast period due to increasing clinical development activities.

By Disease

Based on disease, the market includes HSDD, dyspareunia, and others. The dyspareunia segment held the largest share of 90.81% in 2026, attributed to its high global prevalence and increased clinical focus. The HSDD segment is projected to grow steadily due to rising awareness and psychological health considerations.

By Route of Administration

The market is categorized into oral, parenteral, and topical routes. The parenteral segment dominated with 70.70% share in 2026, owing to advantages such as localized drug delivery and reduced systemic side effects. However, topical therapies are expected to gain traction with ongoing product innovations.

By Distribution Channel

Hospital pharmacies accounted for 65.55% share in 2026, driven by increased hospital visits and strong availability of prescription therapies. Retail and online pharmacies are also expanding rapidly due to convenience and telehealth integration.

Regional Insights

North America led the market with USD 477.39 million in 2025, supported by advanced healthcare infrastructure, high awareness, and product approvals. Europe holds the second-largest share due to active clinical research and regulatory initiatives. Asia Pacific is projected to witness the highest CAGR, driven by rising awareness, growing elderly female populations, and improved healthcare access. Latin America and the Middle East & Africa are expected to grow moderately with increasing regulatory initiatives and disease awareness.

Competitive Landscape

The market is relatively consolidated, with major players such as Pfizer Inc., Duchesnay Pharmaceutical Group Inc., Mayne Pharma Group Limited, PALATIN, and Sprout Pharmaceuticals leading the industry. Strong product portfolios, strategic partnerships, and licensing agreements are key competitive strategies.

Conclusion

The global female sexual dysfunction treatment market is poised for substantial growth, increasing from USD 537.19 million in 2025 to USD 595.74 million in 2026, and projected to reach USD 1,655.08 million by 2034 at a CAGR of 13.62%. Rising disease prevalence, strong R&D investments, growing awareness of women's sexual health, and expanded telehealth services are key drivers. Despite challenges such as low awareness and social stigma, continuous innovation and regulatory advancements are expected to support sustained long-term market expansion worldwide.

Growth Rate CAGR of 13.62% from 2026-2034

Segmentation By Drug

• Flibanserin
• Bremelanotide
• Ospemifene
• Estrogen Therapy
• Others

By Disease

• Hypoactive Sexual Desire Disorder (HSDD)
• Dyspareunia
• Others

By Route of Administration

• Oral
• Parenteral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug, Disease, Route of Administration, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Drug, Disease, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific (By Drug, Disease, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Rest of the World (By Drug, Disease, Route of Administration, and Distribution Channel)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases - by Key Countries/Sub-regions, 2025
• 4.2. Pipeline Analysis
• 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.4. Impact of COVID-19 on the Global Market

5. Global Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug
  • 5.1.1. Flibanserin
  • 5.1.2. Bremelanotide
  • 5.1.3. Ospemifene
  • 5.1.4. Estrogen Therapy
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease
  • 5.2.1. Hypoactive Sexual Desire Disorder (HSDD)
  • 5.2.2. Dyspareunia
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
  • 5.3.3. Topical
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Drug Stores & Retail Pharmacies
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East and Africa

6. North America Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug
  • 6.1.1. Flibanserin
  • 6.1.2. Bremelanotide
  • 6.1.3. Ospemifene
  • 6.1.4. Estrogen Therapy
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease
  • 6.2.1. Hypoactive Sexual Desire Disorder (HSDD)
  • 6.2.2. Dyspareunia
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
  • 6.3.3. Topical
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Drug Stores & Retail Pharmacies
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 6.5.1. U.K.
  • 6.5.2. Germany
  • 6.5.3. France
  • 6.5.4. Spain
  • 6.5.5. Italy
  • 6.5.6. Rest of Europe

7. Asia Pacific Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug
  • 7.1.1. Flibanserin
  • 7.1.2. Bremelanotide
  • 7.1.3. Ospemifene
  • 7.1.4. Estrogen Therapy
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease
  • 7.2.1. Hypoactive Sexual Desire Disorder (HSDD)
  • 7.2.2. Dyspareunia
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Topical
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Drug Stores & Retail Pharmacies
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. Japan
  • 7.5.2. China
  • 7.5.3. India
  • 7.5.4. Australia
  • 7.5.5. Southeast Asia
  • 7.5.6. Rest of Asia Pacific

8. Latin America Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug
  • 8.1.1. Flibanserin
  • 8.1.2. Bremelanotide
  • 8.1.3. Ospemifene
  • 8.1.4. Estrogen Therapy
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease
  • 8.2.1. Hypoactive Sexual Desire Disorder (HSDD)
  • 8.2.2. Dyspareunia
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
  • 8.3.3. Topical
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Drug Stores & Retail Pharmacies
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Brazil
  • 8.5.2. Mexico
  • 8.5.3. Rest of Latin America

9. Middle East & Africa Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug
  • 9.1.1. Flibanserin
  • 9.1.2. Bremelanotide
  • 9.1.3. Ospemifene
  • 9.1.4. Estrogen Therapy
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease
  • 9.2.1. Hypoactive Sexual Desire Disorder (HSDD)
  • 9.2.2. Dyspareunia
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
  • 9.3.3. Topical
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Drug Stores & Retail Pharmacies
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. GCC
  • 9.5.2. South Africa
  • 9.5.3. Rest of Middle East & Africa

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Sprout Pharmaceuticals, Inc.
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. financials (Based on Availability)
  • 10.2.2. Mayne Pharma Group Limited
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. financials (Based on Availability)
  • 10.2.3. Duchesnay Pharmaceutical Group Inc.
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. financials (Based on Availability)
  • 10.2.4. PALATIN
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. financials (Based on Availability)
  • 10.2.5. Freya Pharma Solutions B.V.
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. financials (Based on Availability)
  • 10.2.6. Acerus Pharmaceuticals Corporation
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. financials (Based on Availability)
  • 10.2.7. Millicent Pharma Ltd. (Endoceutics, Inc.)
    • 10.2.7.1. Overview
    • 10.2.7.2. Products
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. financials (Based on Availability)
  • 10.2.8. Pfizer Inc.
    • 10.2.8.1. Overview
    • 10.2.8.2. Products
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. financials (Based on Availability)